Table 1.
Baseline Characteristics of Lung Transplant Patients With COVID-19
| Variable | All patients | Hospitalized | Non-hospitalized | p-valuea | Died | p-valueb |
|---|---|---|---|---|---|---|
| Recipients, n (%) | 74 (100) | 42 (57) | 32 (43) | 15 (20) | ||
| Age, years | 59 (48-65) | 63 (54-67) | 54 (39-63) | 0.010 | 63 (49-71) | 0.010 |
| Gender, male (%) | 45 (61) | 24 (57) | 21 (66) | 0.459 | 9 (60) | 0.943 |
| Non-Caucasian, n (%) | 9 (12) | 6 (14) | 3 (9) | 0.522 | 2 (13) | 0.876 |
| Transplant indication, n (%) | ||||||
| COPD | 29 (39) | 18 (43) | 11 (34) | 9 (60) | ||
| Fibrosis | 21 (28) | 13 (31) | 8 (25) | 2 (13) | ||
| Pulmonary hypertension | 5 (7) | 2 (5) | 3 (9) | 0 (0) | ||
| Cystic fibrosis | 15 (20) | 6 (14) | 9 (28) | 3 (20) | ||
| Other | 4 (5) | 3 (7) | 1 (3) | 1 (6) | ||
| Bilateral LTx, n (%) | 64 (87) | 35 (83) | 29 (91) | 0.363 | 11 (73) | 0.095 |
| Time since transplant, years | 5 (2-10) | 6 (2-10) | 5 (1-11) | 0.477 | 8 (2-11) | 0.477 |
| Body mass index, kg/m2 | 26 (24-29) | 28 (24-32) | 25 (23-27) | 0.036 | 27 (20-32) | 0.036 |
| Comorbidities, n (%) | ||||||
| Hypertension | 27 (37) | 18 (43) | 9 (28) | 0.192 | 5 (33) | 0.776 |
| Dyslipidemia | 7 (10) | 2 (6) | 5 (16) | 0.114 | 1 (7) | 0.679 |
| Diabetes Mellitus | 25 (34) | 20 (48) | 5 (16) | 0.004 | 11 (73) | 0.000 |
| Chronic kidney disease | 45 (61) | 30 (71) | 15 (47) | 0.032 | 13 (87) | 0.022 |
| Atrial fibrillation | 3 (4) | 2 (5) | 1 (3) | 0.724 | 0 (0) | 0.373 |
| Heart failure | 4 (5) | 3 (7) | 1 (3) | 0.449 | 1 (7) | 0.809 |
| Immunosuppression, n (%) | ||||||
| Tacrolimus | 71 (96) | 40 (95) | 31(97) | 14 (93) | ||
| CYC | 2 (3) | 1 (2) | 1 (3) | 0 (0) | ||
| AZA | 6 (8) | 3 (9) | 3 (9) | 1 (7) | ||
| MMF | 65 (87) | 37 (88) | 28 (88) | 12 (80) | ||
| mTORi | 8 (11) | 6 (14) | 2 (6) | 4 (27) | ||
| COVID-19 vaccination, n (%)c |
7 (10) | 5 (12) | 2 (6) | 0 (0) |
AZA, azathioprine; COPD, chronic obstructive pulmonary disease; CYC, cyclosporine; LTx, lung transplantation; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitors (everolimus or sirolimus).
Continuous variables are expressed as median (interquartile range).
a
p-value for the difference between hospitalized patients and non-hospitalized patients.
b
p-value for the difference between survivors and non-survivors.
c
The vaccine used was mRNA (Moderna).